Market Watch: Japan - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Market Watch: Japan


Pharmaceutical Technology


(IMAGEZOO/IMAGES.COM/GETTY IMAGES)
According to the latest figures from IMS Health, Inc., Japan's pharmaceutical market is expected to grow 1–2% this year compared to global industry growth expectations of 5–6%. Despite the lower forecast, Japan is still the largest market in the Asia-Pacific region and the second largest individual market in the world after the US. But China and India are catching up. According to IMS Health's 2006 world market report, Japan's pharmaceutical sales declined by 0.4% between 2005 and 2006 to $64 billion, whereas China's sales grew 12.3% to $13.4 billion, and India's grew 17.5% to $7.3 billion during the same time period.

One reason Japan's industry may not be growing as quickly compared to other parts of the world may be the country's regulatory system. It takes an average of four years to get a new drug approved compared to the average 18 months it takes in the United States and Europe. As a result, far fewer drugs are available in Japan and those that are available worldwide take much longer to hit the Japanese market.


Fast facts:
But the Japanese aren't just sitting back and watching their numbers slide. Just last year, the country's Pharmaceuticals and Medical Devices Agency set out to hire 240 new drug reviewers over a period of three years to help bring its drug approval process more in line with US and European timeframes. Also in 2007, Japan launched a five-year action plan (2007–2011) and "new vision" for its pharmaceutical industry. After a series of dialogues between government, industry, and academia, a group of representatives agreed to focus on innovation and international competitiveness, according to progress reports from Japan's Pharmaceutical Manufacturers Association (JPMA), a 75-member organization. Among the action plan goals are the creation of a New Drug Research Promotion Council, financial aid for medical institutions to carry out clinical research, greater industry-government collaboration, and personnel development geared toward drug discovery.

Japan's expenditures for research and development (R&D) in 2004, the latest data available according to the Japanese Ministry of Internal Affairs and Communications, totaled $907.7 billion as compared to $642.2 billion approximately a decade earlier. The largest Japanese companies (Takeda, Astellas, Eisai, Daiichi and Sankyo, Chugai, Shionogi, Tanabe, and Taisho), reports JPMA, spent an average of 14.2% of their sales on R&D in 2004 as compared to 11.1% in 1999.

With even more resources, collaboration, and attention being paid to the R&D side of Japan's pharmaceutical market, it looks as though the country intends to catch up to the US, or at least make sure it stays ahead of its Asian-Pacific neighbors.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here